NAT2 slow acetylation and bladder cancer risk: A meta-analysis of 22 case-control studies conducted in the general population

Pharmacogenetics

Volumn 10, Issue 2, 2000, Pages 115-122

  Marcus, Pamela M ^a   Vineis, Paolo ^b   Rothman, Nathaniel ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Arylamine n acetyltransferase; Bladder neoplasms; Meta analysis

Indexed keywords

CARCINOGEN; MONOAMINE;

ACETYLATION; ALLELE; ARTICLE; BLADDER CANCER; CANCER GENETICS; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACETYLATION; DRUG DETOXIFICATION; FEMALE; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PHENOTYPE; POPULATION GENETICS; PRIORITY JOURNAL; STATISTICS;

EID: 0034027832     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200003000-00003     Document Type: Article

References (53)

1. Blum M, Demierre A, Grant D, Heim M, Meyer U. Molecular mechanisms of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991; 88:5237-5241.
2. Breslow NE, Day NE. Statistical methods in cancer research, vol. 1 - the analysis of case-control studies. Lyon: International Agency for Research on Cancer; 1980.
3. Brockmöller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferase M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996;56:3915-3925.
4. Cartwright RA, Rogers HJ, Barham-Hall D, Slashan RW, Ahmod RA, Higgins E, et al. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982; 2:842-845.
5. Cartwright R. Epidemiologic studies on N-acetylation and C-center ring oxidation in neoplasia. In: Omenn GS, Gelboin, HV, editors. Banbury report 16: genetic variability in responses to chemical exposure. Cold Spring Harbor: Cold Spring Harbor Laboratory; 1984, pp. 359-368.
6. Cascorbi I, Drakoulis N, Brockmöller J. Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995; 57:581-592.
7. Census of Population and Housing 1990. Internet site http://venus.census.gov/cdrom/lookup/ (database STF3c, part 1). Washington, DC: The Bureau of the Census; 1992.
8. D'Errico A, Taoli E, Chen X, Veneis P. Genetic metabolism polymorphisms and the risk of cancer: a review of the literature. Biomarkers 1996; 1:149-173.
9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
10. Dewan A, Chattopadhyay P, Kulkarni PK. N-acetyltransferase activity - a susceptibility factor in human bladder carcinogenesis. Indian J Cancer 1995; 32:15-19.
11. Ellard G, Gammon P, Tiitinen H. Determination of the acetylator phenotype, using matrix isoniazid. Tubercle 1975; 56: 203-209.
12. Evans DAP, Eze LC, Whibley EJ. The association of the slow acetylator phenotype with bladder cancer. J Med Genet 1983; 20:330-333.
13. Fantoli U, Cattaneo C, Ritis G, Balasio L. Metabolismo de'idrazide dell'acido isonicotinico. Ann Inst Forl 1963; 23:115-142.
14. Golka K, Prior V, Blaszkewicz M, Cascorbi I, Schops W, Kierfeld G, et al. Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany. Scand J Work Environ Health 1996; 22:332-338.
15. Graf T, Broly F, Hoffmann F, Probst M, Meyer U, Howald H. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol 1992; 43:399-403.
16. Hanke J, Krajewska B. Acetylation phenotypes and bladder cancer. J Occup Med 1990; 32:917-918.
17. Hanssen HP, Agarwal DP, Goedde HW, Bucher H, Huland H, Brachmann W, et al. Association of N-acelyltransferase polymorphism and environmental factors with bladder carcinogenesis. Eur Urol 1985; 11:263-266.
18. Hayes RB, Bi W, Rothman N, Broly F, Caporaso N. Feng P, et al. N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis 1993; 14:675-678.
19. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 1988; 948:37-66.
20. Hickman D, Sim E. N-acelyltransferase polymorphism: comparison of phenotype and genotype in humans. Biochem Pharmacol 1991; 42: 1007-1014.
21. Holland P, Barry M, Feely J. Pharmacogenetics and drug metabolism: an Irish perspective. Irish J Med Sci 1991; 160:54-56.
22. Horai Y, Fujita K, Ishizaki T. Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer. Eur J Clin Pharmacol 1989; 37:581-587.
23. Hubbard A, Harrison D, Moyes C, Wyllie A, Cunningham C, Mannion E, et al. N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions. Gut 1997; 41:229-234.
24. Ishizu S, Hashida C, Hanaoka T, Maeda K, Ohishi Y. N-Acetyltransferase activity in the urine in Japanese subjects: comparison in healthy persons and bladder cancer patients. Jap J Cancer Res 1995; 86:1179-1181.
25. Iwainsky H, Gerloff W, Schmeidel A. Die differenzierung zwischen INH-Inaktivierern under normal abbauden patienten mit hilfe eines einfachen testes. Betir Klin Tuberk 1961; 124:384-389.
26. Kaisary A, Smith P. Jaczq E, McAllister B, Wilkinson GR, Ray WA, et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987; 47:5488-5493.
27. Karakaya AE, Cok I, Sardas S, Gogus O, Sardas OS. N-acetyltransferase phenotype of patients with bladder cancer. Hum Toxicol 1986; 5:333-335.
28. Katoh T, Inatomi H, Yang MH, Kawamoto T, Matsumoto T, Bell DA. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and risk of urothelial transitional cell carcinoma among Japanese. Pharmacogenetics 1999; 9:401-404.
29. Kergueris M, Bourin M, Larousse C. Pharmacokinetics of isoniazid: influence of age. Eur J Clin Pharmacol 1986; 30:335-340.
30. Ladero JM, Kwok CK, Jara C, Fernández L, Silmi AM, Tapia D, et al. Hepatic acetylator phenotype in bladder cancer patients. Ann Clin Res 1985; 17:96-99.
31. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Techol Assess Health Care 1990; 6:5-30.
32. Lander ES, Schork NJ. Genetic dissection of complex traits. Science 1994; 265:2037-2048.
33. Lower GM, Bryan GT. Etiology and carcinogenesis: natural systems approaches to causality and control. In: Javadpour N, editor. Principles and management of urologic cancer. Baltimore: Williams and Wilkins; 1979.
34. Lower GM, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect 1979; 29:71-79.
35. Miller ME, Cosgriff JM. Acetylator phenotype in human bladder cancer. J Urol 1983; 130:65-66.
36. Mommsen S, Barford NM, Aagaard J. N-acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population. Carcinogenesis 1985; 6:199-201.
37. Mrozikiewicz P, Drakoulis N, Roots I. Polymorphic arylamine N-acetyltransferase (NAT2) genes in children with insulin-dependent diabetes mellitus. Clin Pharm Ther 1994; 56:626-634.
38. Okkels H, Sigsgaard T, Wolf H, Autrup H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev 1997; 6:225-231.
39. Peluso M, Airoldi L, Armelle M, Martone T, Coda R, Malaveille C, et al. White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1998; 7:341-346.
40. Risch A, Wallace DMA, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 1995; 4:231-236.
41. Roots I, Drakoulis N, Brockmöller J, Janicke I, Cuprunov M, Ritter J. Hydroxylation and acetylation phenotypes as genetic risk factors in certain malignancies. In: Kato R, Estabrook RW, Cayen MN, editors. Xenobiotic metabolism and disposition. London: Taylor and Francis; 1989. pp. 499-506.
42. Rothman N, Stewart W, Caporaso N, Hayes R. Misclassification of genetic susceptibility biomarkers: implications for case-control studies and cross-population comparisons. Cancer Epidemiol Biomarkers Prev 1993; 2:299-303.
43. SAS Institute Inc. SAS/STAT software: changes and enhancements through release 6.11. Cary, NC: SAS Institute; 1996.
44. Silverman DT, Morrison AS, Devesa SS. Bladder cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention. New York: Oxford University Press; 1996.
45. Su HJ. Guo YL, Lai M, Huang J, Chng Y. Christiani DC. The NAT2* slow acetylator genotype is associated with bladder cancer in Taiwanese, but not in the Black Foot Disease endemic area population. Pharmacogenetics 1998; 8:187-190.
46. Taylor JA, Umbach DM, Stephens E, Castranio T, Paulson D, Robertson C, et al. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res 1998; 58:3603-3610.
47. Tiemersma E, Kampman E, Bunschoten J, Bussemakers M, Kiermeney L. Genetic polymorphisms of GSTM1, GSTP1, NAT1, NAT2 in smoking-associated bladder. Proc Am Assoc Cancer Res 1999; 40:89.
48. Vineis P, Pirastu R. Aromatic amines and cancer. Cancer Causes Control 1997; 8:346-355.
49. Weber WW. The acetylator genes and drug response. New York: Oxford University Press; 1987.
50. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991; 10:1665-1677.
51. Woodhouse KW, Adams PC, Clothier A, Mucklow JD, Rawlins MD. N-acelylation phenotype in bladder cancer. Hum Toxicol 1982; 1:443-445.
52. World Health Organization. Cancer incidence in five continents, vol. VII. Lyon: International Agency for Research on Cancer; 1997.
53. Yu MC, Skipper PL, Taghizadeh K, Tannenbaum SR, Chan KK, Henderson BE, et al. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J Natl Cancer Inst 1994; 86:712-716.